ArticleCNS neuroscience & therapeutics2026
miR-15a-5p Regulates Ferroptosis in Glioblastoma by Targeting GLS2.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimsGlioblastoma (GBM) remains the most lethal primary brain tumor, and the molecular mechanisms driving its aggressiveness are incompletely understood. Recent multi-omics analyses have identified miR-15a-5p as one of the core microRNAs most closely associated with GBM. This study aimed to investigate the functional role and mechanism of miR-15a-5p in GBM pathogenesis.
methodsExpression of miR-15a-5p was analyzed in GBM tissues and cell lines. Genetic silencing experiments were performed to assess cell proliferation, migration, and tumor growth across multiple GBM cell lines and in an intracranial xenograft model. Ferroptosis-related changes were evaluated, and target validation was conducted using luciferase reporter assays. Rescue experiments were performed by co-modulating miR-15a-5p and GLS2.
resultsmiR-15a-5p was significantly overexpressed in GBM tissues and cell lines, and high expression correlated with poor patient survival. Genetic silencing of miR-15a-5p suppressed GBM cell proliferation and migration and inhibited tumor growth in vivo. Mechanistically, miR-15a-5p directly targeted the 3'UTR of glutaminase 2 (GLS2). Knockdown of miR-15a-5p induced ferroptosis-related features, including GPX4 downregulation, ACSL4 upregulation, iron accumulation, lipid peroxidation, and mitochondrial contraction. These effects were reversed by GLS2 knockdown in both in vitro and in vivo rescue experiments.
conclusionThe miR-15a-5p/GLS2 axis represents a previously unrecognized mechanism by which GBM cells resist ferroptosis. These findings not only define a novel mechanism underlying ferroptosis regulation in GBM but also identify the miR-15a-5p/GLS2 axis as a potential entry point for ferroptosis-based therapeutic intervention. Targeting this axis may provide a rational strategy to modulate ferroptosis and suppress GBM progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.